97 related articles for article (PubMed ID: 8639496)
1. Inhibition of human steroid 5alpha reductases type I and II by 6-aza-steroids: structural determinants of one-step vs two-step mechanism.
Moss ML; Kuzmic P; Stuart JD; Tian G; Peranteau AG; Frye SV; Kadwell SH; Kost TA; Overton LK; Patel IR
Biochemistry; 1996 Mar; 35(11):3457-64. PubMed ID: 8639496
[TBL] [Abstract][Full Text] [Related]
2. 19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
Guarna A; Belle C; Machetti F; Occhiato EG; Payne AH; Cassiani C; Comerci A; Danza G; De Bellis A; Dini S; Marrucci A; Serio M
J Med Chem; 1997 Mar; 40(7):1112-29. PubMed ID: 9089333
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5alpha-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat.
Stuart JD; Lee FW; Simpson Noel D; Kadwell SH; Overton LK; Hoffman CR; Kost TA; Tippin TK; Yeager RL; Batchelor KW; Bramson HN
Biochem Pharmacol; 2001 Oct; 62(7):933-42. PubMed ID: 11543729
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.
Makridakis N; Reichardt JK
J Mol Endocrinol; 2005 Jun; 34(3):617-23. PubMed ID: 15956333
[TBL] [Abstract][Full Text] [Related]
5. Linear relationships between the ligand binding energy and the activation energy of time-dependent inhibition of steroid 5alpha-reductase by delta 1-4-azasteroids.
Tian G; Haffner CD
J Biol Chem; 2001 Jun; 276(24):21359-64. PubMed ID: 11279132
[TBL] [Abstract][Full Text] [Related]
6. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.
Gisleskog PO; Hermann D; Hammarlund-Udenaes M; Karlsson MO
Clin Pharmacol Ther; 1998 Dec; 64(6):636-47. PubMed ID: 9871428
[TBL] [Abstract][Full Text] [Related]
7. New approach to 3-oxo-4-aza-5alpha-androst-1-ene-17beta-(N-tert-butylcarboxamide).
Jiang ZX; Ye JQ; Jiang L; Zhao YS
Steroids; 2005 Sep; 70(10):690-3. PubMed ID: 15896818
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
9. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
[TBL] [Abstract][Full Text] [Related]
10. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
11. 3,3-diphenylpentane skeleton as a steroid skeleton substitute: novel inhibitors of human 5alpha-reductase 1.
Hosoda S; Hashimoto Y
Bioorg Med Chem Lett; 2007 Oct; 17(19):5414-8. PubMed ID: 17686629
[TBL] [Abstract][Full Text] [Related]
12. Actions of 5alpha-reductase inhibitors on the epididymis.
Robaire B; Henderson NA
Mol Cell Endocrinol; 2006 May; 250(1-2):190-5. PubMed ID: 16476520
[TBL] [Abstract][Full Text] [Related]
13. Doping-control analysis of the 5alpha-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite.
Thevis M; Geyer H; Mareck U; Flenker U; Schänzer W
Ther Drug Monit; 2007 Apr; 29(2):236-47. PubMed ID: 17417080
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies.
Tian G; Mook RA; Moss ML; Frye SV
Biochemistry; 1995 Oct; 34(41):13453-9. PubMed ID: 7577933
[TBL] [Abstract][Full Text] [Related]
15. [Epididymis in an experimental model of DHT deficiency: immunolocalization of ERalpha and ERbeta in rat epididymal epithelial cells. In vivo and in vitro studies].
Kolasa A
Ann Acad Med Stetin; 2006; 52(2):13-21; discussion 21. PubMed ID: 17633123
[TBL] [Abstract][Full Text] [Related]
16. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
Festuccia C; Gravina GL; Muzi P; Pomante R; Angelucci A; Vicentini C; Bologna M
J Urol; 2008 Jul; 180(1):367-72. PubMed ID: 18499161
[TBL] [Abstract][Full Text] [Related]
17. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
Olsen EA; Hordinsky M; Whiting D; Stough D; Hobbs S; Ellis ML; Wilson T; Rittmaster RS;
J Am Acad Dermatol; 2006 Dec; 55(6):1014-23. PubMed ID: 17110217
[TBL] [Abstract][Full Text] [Related]
18. Effects of various pesticides on human 5alpha-reductase activity in prostate and LNCaP cells.
Lo S; King I; Alléra A; Klingmüller D
Toxicol In Vitro; 2007 Apr; 21(3):502-8. PubMed ID: 17218080
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of rat alpha-reductases by finasteride: evidence for isozyme differences in the mechanism of inhibition.
Azzolina B; Ellsworth K; Andersson S; Geissler W; Bull HG; Harris GS
J Steroid Biochem Mol Biol; 1997 Apr; 61(1-2):55-64. PubMed ID: 9328210
[TBL] [Abstract][Full Text] [Related]
20. A novel in vitro model to screen steroid 5 alpha-reductase inhibitors against benign prostatic hyperplasia.
Sun ZY; Tu ZH
Methods Find Exp Clin Pharmacol; 1998 May; 20(4):283-7. PubMed ID: 9658376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
